Inhalation Asia 2019 Conference

Inhalation Asia Conference presentation covering analytical strategies to accelerate generic OINDP development

We are pleased to be a Gold Sponsor of the Inhalation Asia 2019 conference, 13-15 November 2019, Hong Kong.

Conference Presentation - Thursday 14th Nov
Session 3 – Developing inhalers
Mark Parry, Technical Director, will present "Analytical strategies to accelerate and simplify generic OINDP development"

In-vitro bioequivalence for the development of generic inhaled pharmaceutical products continues to provide challenges to the industry in developing and performing suitable analytical strategies to both satisfy the continuously evolving requirements of the regulators, and ensure a robust development process that ensure the developed generic product is successful. In this conference presentation, Mark Parry, will discuss the key regulatory aspects and analytical strategies to underpin the development of stronger in-vivo data packages supporting both greater clinical success and the possibility of successful in-vitro only generic approvals. 

    Contact us to request further information.  

    Our experts will be at available during the exhibition to provide updates on the latest developments in our inhaled product development capabilities. Intertek’s integrated formulation and analytical experts undertake early stage pre-formulation support, formulation development, inhalation product analysis and testing, solubility screening, drug-excipient compatibility, stability testing and device selection support to aid clients working to develop formulations targeting specific regions of the respiratory tract or nasal cavity.  

    A Review of In-vitro Testing for Bioequivalence of Nasal Drug Products
    WEBINAR RECORDING: Advanced analytical techniques for testing OINDPs   
    ARTICLE DOWNLOAD: Developing Inhaled and Nasal Biologics
    BROCHURE: Intertek Inhaled Product Development Brochure 



    Inhalation Asia is a pulmonary and intranasal drug delivery conference, helping to promote R&D activities, with topics ranging across inhalation research (pharmaceutics / clinical / pharmacological / pharmacokinetics / formulation / performance testing / chemical), products, technologies, regulatory issues and insights into pulmonary and intranasal drug delivery.
    Need help or have a question? +1 800 967 5352

    Need help or have a question?

    +1 800 967 5352
    EMEA UK:
    +44 161 721 5247
    +41 61 686 4800